2018
DOI: 10.4049/jimmunol.1701039
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Agonists to the TNF/TNFR costimulatory receptors CD134 (OX40) and CD137 (4-1BB) elicit antitumor immunity. Dual costimulation with anti-CD134 plus anti-CD137 is particularly potent because it programs cytotoxic potential in CD8 and CD4 T cells. Cytotoxicity in dual-costimulated CD4 T cells depends on the T-box transcription factor eomesodermin (Eomes), which we report is induced via a mechanism that does not rely on IL-2, in contrast to CD8 CTL, but rather depends on the CD8 T cell lineage commitment transcrip… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 63 publications
(154 reference statements)
0
8
1
Order By: Relevance
“…Dual costimulation enhanced T-bet in the specific CD4 T cells derived from the High mice (Figures 1E and 1F), whereas Eomes was greatly increased in the same cells when primed in the Low mice. This is an interesting contrast since our previous data show that dual costimulation and other data using CD137 costimulation alone induce Eomes (Curran et al, 2013; Mittal et al, 2018; Qui et al, 2011); however, in the High mice we detected T-bet and very little Eomes. It is possible that Eomes may have an altered kinetic profile under certain conditions, although the up-regulation of granzyme B in T-bet + Eomes − CD4 T cells was unexpected.…”
Section: Discussioncontrasting
confidence: 99%
“…Dual costimulation enhanced T-bet in the specific CD4 T cells derived from the High mice (Figures 1E and 1F), whereas Eomes was greatly increased in the same cells when primed in the Low mice. This is an interesting contrast since our previous data show that dual costimulation and other data using CD137 costimulation alone induce Eomes (Curran et al, 2013; Mittal et al, 2018; Qui et al, 2011); however, in the High mice we detected T-bet and very little Eomes. It is possible that Eomes may have an altered kinetic profile under certain conditions, although the up-regulation of granzyme B in T-bet + Eomes − CD4 T cells was unexpected.…”
Section: Discussioncontrasting
confidence: 99%
“…This contrasts with a report indicating that overexpression of Eomes induces cytotoxic function in CD4 T cell lines, suggesting that this TF may promote cytotoxicity when expressed at high levels in CD4 T cells, as observed in CD8 T cells ( Pearce et al, 2003 ; Eshima et al, 2012 ; Intlekofer et al, 2008 ). The role of Eomes could also be restricted to specific conditions of co-stimulation as recently reported ( Mittal et al, 2018 ). The expression of Hopx by CD4 CTX T cells showed a similar pattern as T-bet and Runx3 both in vivo and in vitro.…”
Section: Discussionmentioning
confidence: 71%
“…11,[60][61][62] To explore whether TSHR-specific T cells exist in the CD4+ KLRG1+ CTL population, an MLR with TSHR 289 was performed. Compared with control or irrelevant antigen ovalbumin (OVA) stimulation, after stimulation with TSHR289 for 24 h or 48 h, CD4+ KLRG1+ CTLs were significantly activated, as indicated by the increased level of CD25+ CD134+ cells 63,64 (0.45% ± 0.16% vs 1.527% ± 0.02667%, P = 0.0027 at 24 h, 0.5267% ± 0.1167% vs 1.697% ± 0.08333%, P = 0.0012 at 48 h, Fig. 5e).…”
Section: Droplet-based Scrna-seq Of Cd4+ T Cells From Go and Gh Patientsmentioning
confidence: 99%